The three cohorts of COVID-19 patients showed a significantly higher percentage of receptor-binding domain (RBD) to angiotensin-converting enzyme-2 (ACE2) interaction inhibition (rNAbs) than the control group (Fig. 1B). The gene discussed is ACE2; the disease is COVID-19.